Press Release: Last patient, last visit completed in Phase I clinical trial of PulseSight Therapeutics’ PST-611 treatment for dry AMD/Geographic Atrophy (GA)
-Results to be presented at ARVO 2026 Annual Meeting- PARIS, April 23, 2026 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, will be presenting the results of its PST-611 phase I clinical trial at the ARVO 2026 Annual Meeting May 3-7 in…
JCDecaux SESociété Européenne à Directoire et Conseil de SurveillanceAu capital de 3.264.372,84 €Siège Social : 17, rue Soyer - 92200 Neuilly-sur-Seine (France)307 570 747 RCS Nanterre Déclaration mensuelle d’actions et de droits de vote
Bank of Spain-regulated card issuer combines human-led and agentic AI pentesting to surface business logic risk and meet regulatory traceability requirements Bank of Spain-regulated card issuer combines human-led and agentic AI pentesting to surface business logic risk and meet regulatory traceability requirements